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INTRODUCTION
1An  ureteric stent, is a  tube that is placed  inside  the ureter to
treat  and  also to  prevent  urinary obstruction . The stent length
ranges from 24 to 30 cm   in adults. Cystoscopic placement is the
common method used tor stenting. Stents used in ureter are called
double J, double pig-tail ,DJ  or JJ stents.
The term stent was first coined by Charles T Stent (1807–
1885), an English dentist. Stents are commonly indicated in urology
for draining urine from the kidney to the bladder. Stenting is mostly
done in the ureter for stone disease during definitive procedures like
ureteroscopy and extracorporeal shock wave lithotripsy. Advances in
instrumentation of ureter have made ureteroscopy less morbid that
the stent placed following the procedure remains the main source of
concern to the patient. The stent that remains in situ usually causes
the symptoms of urinary tract infection, pain in the suprapubic
region and flank due to urinary reflux, frequency, urgency, dysuria
and hematuria(1).
An ideal stent material should be biocompatible, radiopaque,
must relieve intraluminal and extra-luminal obstructions, must be
resistant to encrustation and infection, cause little discomfort to the
2patient, and has to be widely available at reasonable cost. Upto date,
no such stent material fits into all these criteria.
An attempt has been made in this study to evaluate the stent
related symptoms after semirigid ureteroscopy and intracorporeal
lithotripsy for mid, lower and distal vesico ureteric junction calculi ,
and a comparison has been made between stented and non stented
patients .
REVIEW OF LITERATURE
3ANATOMY
The ureter is 22 to 30 cm long, and it  transports urine from the
renal pelvis to the urinary bladder. The renal pelvis may be
intrarenal or extrarenal. It has a capacity of 3 to 10 ml. The  ureter
begins at the level of first lumbar vertebra. The right ureter is
roughly 1 cm shorter than the left ureter. The ureter has an S shaped
course in both the transverse and sagittal planes.
There  are three narrow points along the course of the ureter
where the calculi frequently get lodged and impacted. Those are the
ureteropelvic junction, point of crossover of the iliac vessels and the
vesicoureteric junction. The latter is the narrowest portion and thus
dilatation of this part, usually causes the rest of the ureter to be
negotiated easily.
 Anatomically the ureter is divided into an abdominal part
above the iliac vessels and a pelvic part below them. The abdominal
ureter runs on the medial aspect of the psoas muscle, covered by
parietal peritoneum and is embedded in subserous fascia. It then
crosses over the terminal part of bifurcation of common iliac vessels
or over the first part of external iliac vessels and becomes the pelvic
4ureter. The pelvic ureter is divided into a lumbar and an iliac
segment, both segments being of 8 cm length. The ureters are only 5
cm away from each other  in the pelvic portion. They diverge and
run inferolaterally along the anterior border of the greater sciatic
notch. Then they curve medially into the bladder  at its lateral angle
and take an oblique 2 cm course  through the wall of the bladder .
RADIOLOGY
Radiologically, the ureter is divided into an upper, middle and
lower part. The upper part is the portion of ureter above the sacral
promontory, middle part runs through the body of sacrum and the
lower part lies below the sacrum. With respect to urolithiasis, the
radiological classification is used commonly.
 In  an  excretory  urogram,  the  right  renal  pelvis  is  usually
opposite to the level of L2 vertebra and the left renal pelvis is
usually 1 to 2 cm higher. The kidneys may move upto 4 cm during
inspiration and the ureters may be kinked, mimicking the appearance
of obstruction. So, urograms obtained in the expiratory phase are
better. The abdominal ureter passes over the lumbar transverse
processes lateral to their pedicles upto the level of L5vertebra, and
5then turns medially. Generally, it is considered pathological if an
ureter is found 1.5 cm lateral to pedicles of the lumbar vertebrae.
Normal Ureteral diameter at various levels
level Diameter (mm) Size (F)
Ureteropelvic
junction 2-4 6-12
abdominal 5-6 15-18
Pelvis 4 12
intramural 1.5-3 5-9
HISTORY OF URETEROSCOPY
It was Hugh Hampton Young, who first inspected the upper
urinary tract by endoscopy in 1912. He used a cystoscope of 9.5 F
size in a pediatric case of megaureter. Lyon and Goodman, in 1977
reported the first usage of rigid ureteroscopes. Eventhough the
advent of fibre optic principles heralded the development of flexible
ureteroscopes, they have not gained universal acceptance in view of
the cost factor and limited capabilities. Initial endoscopes consisted
6of relay lenses arranged serially within a hollow tube. The invention
of rod lens system by Harold Hopkins revolutionalised the field of
endoscopy. It consists of glass rods that substituted the air spaces in
the older version of endoscopes. Between the rods are air spaces,
that serve as relay lenses. Endoscopic instruments specifically meant
for ureteroscopy were initially made by Richard Wolf, the use of
which has been reported as early as 1979. Thereafter various sizes of
sheaths and working lengths were developed. The incorporation of
rod lens system along small size sheaths have enabled ureteroscopy
less morbid in recent times.
STENTS
Endoscopic placement of stents to relieve obstruction of the
ureter was first described in 1967  by Zimskind. Double J stents and
pigtail stent were first introduced by Finney and Hepperlen in 1978.
Stenting is done to drain urine through the ureters , in cases of
ureteral obstruction due to stones and other causes like papillary
necrosis. Stents are known in urology as double J stents owing to the
shape of the coils produced at both the ends in the shape of a J. They
are also known as JJ or DJ stents. They are available in different
7sizes and lengths. Stents can be open at both ends or have one closed
end. The flow of urine in stented patients is facilitated around the
stent as it acts as a scaffolding for the ureters.
Indications:
? Extrinsic ureteral obstruction  due to retroperitoneal
fibrosis and tumours
? intrinsic obstruction of the ureter as a result of stone
disease, stricture and tumours.
In both these circumstances, stenting can be either a temporary
measure when definitive treatment is being  instituted or as a
permanent procedure when no definitive treatment is possible such
as
? In cases of bilateral obstruction,
? solitary kidney status (anatomically  or functionally)
? refractory renal colic
? refractory ureteric obstruction .
8Stenting  is done  as an emergency when obstruction is
associated with signs of infection, namely pyuria, leucocytosis and
fever.  During percutaneous stone removal procedures, ureteral
stenting is indicated in the following situations
? associated collecting system perforation
? when the stone burden is high and there is a need for
ancillary procedures like extracorporeal shock wave
lithotripsy
? edema causing obstruction of the ureter
? coexisting uretero pelvic junction obstruction
? migration of stone fragments into the ureter
? supracostal access
? urinary fistula after removal of nephrostomy tube which
      is persistent.
Following ureteroscopy for calculi , stenting  is indicated
when
9? calculus impaction is present
? when stone fragmentation is incomplete
? if ureteral dilatation is done during the procedure
? when ureteral perforation occurs during  the procedure.
Stents provide the following advantages in ureteroscopy done
for calculus disease
? ureteral edema, which is transient following the
       procedure is byepassed
? stents causes passive dilatation of the ureter, thus aiding
       in passage of stone fragments
When endopyelotomy or endoureterotomy are performed, a
stent that is placed following the procedure aids flow of urine and
prevents formation of stricture in the portion of ureter that is incised.
In this clinical setting, to aid in complete regeneration of urothelium
and avoid stenosis the stent has to be left in place for 6 weeks. This
is based on the studies of regeneration of urothelium following
Davies intubated ureterotomy.
10
 A stent that is placed following a clinical scenario of either
suspected or obvious urinary extravasation due to perforation of the
collecting system or ureter, has to be left indwelling for a period of
10 to 14 days. Following ureteroscopic surgery done for upper tract
transitional cell carcinoma, stenting period should be upto 1 week in
uncomplicated cases.
Stenting of ureter prior to extracorporeal shockwave lithotripsy is
indicated
? when stone bulk is more than 2 cm
? extracorporeal shockwave lithotripsy has to be done
bilaterally
? in cases of solitary renal status.
? for management of steinstrasse complicating
extracorporeal shockwave lithotripsy
Stents can be used for identifying ureter to avoid iatrogenic
injury as a landmark during surgery. During laparoscopic surgery,
stents that emit light have been used in order to counteract for the
lack of tactile sensation and for better visualisation.
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When stenting is done in pregnant females for stone disease,
consideration  has  to  be  given  for  frequent  stent  change  every  6
weeks , due to the increased occurrence of encrustation of stents as a
result of increased excretion of uric acid and calcium in urine.
Moreover, the incidence of stent related irritative lower urinary tract
symptoms  is severe due to the overactive bladder symptoms that
occur in later stages of pregnancy.
Stents are also indicated in cases of
? upper urinary tract fistula from a renal or ureteral source
? retroperitoneal urinomas following blunt or open trauma
Stent material should be biocompatible, that is there should not
be any tissue reaction and the immune system must not alter or
affect it. Immune system stimulation can lead to activation of
neutrophils and macrophages and as a result, an inflammatory
response ensues due to a foreign material(2,3).  Pain  and  impaired
tissue healing occur as a result of inflammation. Hyprophobic nature
and charge are notable properties of the stent material, alterations of
which can lead to beneficial effects on the patient. Stent related
symptoms can thus be remarkably reduced. In patients undergoing
12
stenting, greater than 80% have symptoms like urinary frequency,
hematuria and flank pain(4).
Stent related symptoms  need to be minimised. Primarily, need
for stenting during a procedure should be considered taking the stent
related morbidity into account. Stent length is a valid factor
contributing to stent outcomes. Short stents carry the possibility of
migration, that may necessitate surgical removal. Long stents are
associated with troublesome symptoms like urgency and frequency,
due to excess material in the bladder. The excess length of the stent
moves in out at the ureterovesical junction, with relatively little
movement intrarenally. In children, a study of 153 patients
determined that a suitable length is equal to the patient age in years
plus 10 cm (5).
Any stent that crosses the bladder midline causes more
irritative lower urinary tract symptoms(6). Researches have described
a number of parameters to determine ideal length of stent like patient
height and ureteral measurement by intravenous urogram. Intra
operative measurement of length of the ureter correlated  better with
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the correct stent length than  with patient height in a study by Jeon
et al (7).
Stent related irritative lower urinary tract symptoms are
reduced by alpha receptor blockers that are orally administered
compared to placebo(8,9,10).Treatment with oral anti inflammatory
agents and narcotics are only effective moderately. Ketorolac, a non
steroidal anti inflammatory drug, effectively reduces stent related
pain events .Therefore, a Ketorolac eluting stent (Lexington stent ;
Boston scientific) was  designed and  tested in 92 pigs over a 3
month period(11). Ketorolac levels were high in the ureter. This study
demonstrated the advantage of less analgesic use in patients who
received the drug eluting stent, but statistically significant
improvement in pain scores was not demonstrated (12).
Stent material and design have undergone various
modifications. Most stents of the day are made of polyurethane
based polymers. Silicone stents have the property of good
biocompatibility, they elicit minimal tissue inflammation , and resist
encrustation and infection(13). However advancing silicone based
stents over a guide wire is difficult as they are soft. Their usage in
14
obstruction due to extrinsic compression is quite impossible as they
possess low tensile strength (14).
An important aspect of stent in cases of malignant obstruction
of ureter caused by bulky lymph nodes or tumor is to resist
compression due to extrinsic pathology. Nephrostomy tube insertion
is often needed in these patients, particularly if there is an
obstruction at the distal ureteric level, where retrograde stent
placement becomes difficult. This problem can be circumvented by
placement of  two double J stents inside the same ureter(15,16) , so that
when there is blockade of one stent, the other stent drains the ureter.
Metallic stents are being used for malignant ureteral
obstruction . They can be left in dwelling for upto12 months  as they
resist encrustation(17,18) .
Adhesion of bacteria to the stent surface results in formation of
biofilms and subsequent infection. Even in patients where the urine
is found to be sterile by culture, the stent surface has been found to
contain adherent bacteria. Hence, culturing of both urine and stent
has to be done in symptomatic stented patients.
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Stent biofilms form a surface to which bacteria can adhere,
thereby acting as  a nidus for infection. Bacterial species such as
Pseudomonas species possess the enzyme urease, which catalyses
conversion of urea to ammonia, thus urinary pH is raised. A higher
pH accounts for crystallization of calcium phosphate and
magnesium, that leads to encrustation and further infection.
Glycosaminoglycan (GAG), is found normally in urine, and inhibits
crystallization naturally. Coating of polyurethane stents and
nephrostomy tubes with heparin—a member of the
Glycosaminoglycan  family—results in decreased biofilm formation
and encrustation for  a period of 6 weeks following implantation in a
study.
Paz et al(19)have showed in their study  that the rate of infection
is higher in patients who are stented on an emergency basis than
elective patients and that stent related infection cannot be prevented
by prophylactic antibiotics.
The bacteria gain access to stent materials by means of
attachment through components of the outer membrane known as
adhesins. Adhesins attach themselves to various components of the
16
cell structure like collagen, laminin, fibronectin or cell membrane
components . As a part of the resistance mechanism, pili  or fimbriae
develop as filamentous processes , that contain adhesin molecules at
their tips. Such type of resistance mechanisms are seen both in gram
negative and gram positive bacteria.
Urinary tract infections are commonly caused by gram
negative enterobacteriae, Escherichia coli being most common.
Uropathogenic Escherichia coli contain pili of the type I variety ,
contributing significantly to urinary tract infection(20). The fimbriae
express a protein component called  fim H, that  binds to molecules
containing mannose moieties and its adherence to stents placed in
the ureter has also been demonstrated(21). Tamm  Horsfall protein
comprises of mannose (22) and demonstrate  affinity for Escherichia
coli species that bind mannose, thus preventing  adhesion of
bacteria  to cells in the bladder (23,24).  Other bacteria like
Pseudomonas aeruginosa and Proteus species also demonstrate
binding to Tamm  horsfall protein laminin, fibronectin, collagen type
I and type IV are also recognised by fim H for binding similar to
Tamm  Horsfall protein (25).
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Drug eluting stents are beginning to show some promise for
managing stent  related events. A stent that elutes triclosan  has been
reported by Chew et al (26).Triclosan is an antibacterial and
antifungal agent. It is a polychlorophenoxy phenol compound.
Triclosan has been demonstrated to inhibit the growth of Proteus
mirabilis, Klebsiella pneumonia, Enterococcus faecalis and
Staphylococcus aureus. The inhibition of  tumor necrosis factor by
triclosan has also been reported by Elwood et al.
A metallic stent that elutes the chemotherapeutic agent
paclitaxel has been reported by  Liatsikos et al(27). Initial reports in
pigs, comparing the paclitaxel eluting stent with non eluting stents as
control  have shown reduced inflammatory and hyperplastic activity
at the tissue level (27).Human trials are being awaited for this stent .
Tachyplesin III , a peptide  with anti bacterial properties has
been tested for stent elution in a trial. Tachyplesin III has been tested
alone and in combination with piperacillin-tazobactum for inhibition
of Pseudomonas aeruginosa(28).  Similar results have been
demonstrated for BMAP-28, a peptide against Staphylococcus
aureus and Enterococcus faecalis by Orlando et al. in animal models.
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Stents that are biodegradable have been contemplated in the
past. A stent, made of caprolactone, glycolic acid  and L-lactide has
been reported. Initial studies in porcine models have demonstrated
reduced rates of infection compared to  polyurethane  stents. A stent
that is biodegradable is presumed to have less attachment to bacteria
and thus reduced incidence of stent related events.
Stent insertion:
  The retrograde approach is used most often than the
antegrade approach. It is employed as an adjunct to ureteroscopy or
extracorporeal shock wave lithotripsy. When using a retrograde
approach fluoroscopy and guide wires are required for retrograde
insertion of stents, irrespective of whether  flexible cystoscopy or
rigid cystoscopy is used. The best and easiest means of placing an
ureteral stent is by advancing it over a guidewire. A guidewire is
initially passed through a cystoscope into the visualised ureteric
orifice. Then a stent that has both ends open is advanced over the
guidewire with a pusher under direct cystoscopic vision of the
ureteric orifice into the ureter to the level of renal pelvis.
Advancement of the stent up the ureter has to be fluoroscopically
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monitored. The stent is let to curl in the bladder when the pusher
becomes visible at the level of the bladder neck, by extracting the
guidewire completely. More reliance has to be placed on
fluoroscopic monitoring rather than cystoscopy when stenting is
done in cases of malignant obstruction and  impacted ureteral stones.
Initial cystoscopy, either rigid or flexible is done, and a floppy tip
guidewire is advanced into the ureteric orifice and coiled in the renal
pelvis using fluoroscopy. Then , the cystoscope is removed and an 8-
to 10-Fr coaxial dilator is advanced under fluoroscopy until the 10-
Fr sheath is at the urethral meatus. The 8-Fr internal dilator is
removed, leaving the 10-Fr outer sheath in situ. Stent that has been
passed into the guidewire is then advanced through the 10-Fr sheath
by using a pusher, that has  a fluoroscopically visible metal band at
its tip. The pusher is then advanced under fluoroscopic guidance to
the upper border of the pubic symphysis in male patients and lower
border of the pubic symphysis  in female patients,  while lower end
of the stent is being stabilised. The 10-Fr sheath and subsequently
the guidewire are removed, allowing the stent to curl in the bladder.
20
COMPLICATIONS
Apart from stent related events that follow stenting, it has
unique complications of migration and encrustation. The occurrence
of stent migration has been reported in the literature in upto 3.7 %.
This is due to discrepancy of ureteric and stent length, the stent
being shorter. Migration can be prevented by attachment of a
withdrawal string at the distal end. It also provides the added benefit
of avoiding cystoscopic stent removal, which adds morbidity to the
patient.
A stent is a foreign material and when exposed to urine for a
longer period of time , is prone to get encrusted. Stent encrustation
tends to get worsened with increased indwelling time and coexisting
infection with urease-producing organisms. Oxalate is normally
broken down in the gastrointestinal tract by the enzyme oxalate
decarboxylase, that is found in a commensal organism Oxalobacter
formigenes. When oxalate is not degraded bacterially and escapes
excretion through faeces, it is absorbed into the bloodstream and
results in filtration  by the kidneys. In kidneys, under certain
circumstances it can combine with calcium to form calcium oxalate
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calculi. The composition of encrustation in a stent is predominantly
calcium based, and so a plain x ray KUB (kidney, ureter, bladder )
gives a good estimate of the degree and extent of  encrustation
around the stent. In cases of radiolucent uric acid stones, where  x
ray cannot reveal the stone, a CT scan and ultrasound are needed. A
rough estimate of the encrustation burden can be made by
multiplying the width and length of the encrustation made out on
imaging. In general, when the stone burden is >400mm2, the patient
needs to be subjected to a multimodality approach for complete
stone clearance. In cases of extensive stone burden, split renal
function needs to be assessed with a radionuclide study. This is for
documentation of preoperative renal function of the affected side.
In cases of minimal encrustation, retrograde cystoscopic
removal can be attempted. It is prudent to visualise the proximal end
of  the stent fluoroscopically during the procedure  to confirm
uncoiling at the proximal end. When resistance is encountered or the
patient complains of pain, the procedure has to be terminated.
Extracorporeal shockwave lithotripsy can be attempted as high
success rates have been reported in this setting. This can be followed
by cystoscopic removal.
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When significant encrustation is noted in the ureter,
ureteroscopy with laser lithotripsy can be attempted. In cases where
simultaneous passage of an ureteroscope is not possible along with
the stent, placement of a new stent alongside the previous one can be
done and interval cystoscopy can be planned later. Meanwhile, the
new stent aids in passive dilatation of the ureter. Significant
encrustation of the distal intravesical portion of the stent can be dealt
with by cystolitholapaxy. When the proximal coil of the stent is
associated with a stone burden of more than 2 cm, percutaneous
stone removal procedures should be undertaken.
AIM
To evaluate the efficacy and complications of Double J
stenting in ureteric calculi patients, who underwent semi rigid
ureteroscopy and pneumatic lithotripsy.
23
MATERIALS  AND
METHODS
24
It is a prospective study conducted from October 2011 to
February 2013. A total of 70 patients were enrolled in the study.
Inclusion criteria:
? Patients who underwent semirigid ureteroscopy for
uncomplicated ureteric calculi.
? Only uncomplicated vesico ureteric junction calculi,
lower ureteric calculi and mid ureteric calculi were
included in the study.
Exclusion criteria:
? Patients with upper ureteric calculi
? Calculi associated with impaction and edema made out
during ureteroscopy
? Calculi associated with difficult entry of ureteroscope
into the  ureteric orifice.
? Patients who underwent balloon dilatation of the ureteric
orifice.
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? Patients with residual stone fragments in the ureter, post
procedure.
The preoperative work up of patients included general physical
examination of the patient, ultrasound KUB (kidney, ureter, bladder)
to make out the site, size of calculus and proximal pelvicalyceal and
ureteric dilatation, plain X-ray KUB (kidney, ureter, bladder) also to
make out the size and location of stone and intravenous urogram to
make out the degree of obstruction caused by the calculus and
excretion status of the renal units. CT scan KUB (kidney, ureter,
bladder) plain was done in cases of suspected radiolucent calculi that
could not be visualised in plain X-ray.
 Under spinal anesthesia, patient was placed in the lithotomy
position with the ipsilateral leg lower and straighter to facilitate easy
ureteroscope entry. Cystoscopy was done using 20 F sheath, 30
degree scope . The entire urethra assessed and bladder visualised for
any associated pathology. Both the ureteric orifices were visualised
and 0.032 inch guidewire passed into the ipsilateral ureter containing
the calculus. Then the cystoscope was removed and 8 F infant
feeding tube passed into the bladder. 8/9.8 F semirigid ureteroscope
26 cms 5 F one end closed DJ stent and the pusher used in the
study
8 / 9.8 F ureteroscope used in the study
26 cms 5 F one end closed DJ stent and the pusher us d in the study
      Plain X-ray KUB ( kidney, ureter, bladder) showing a
right vesico ureteric junction calculus.
Plain CT KUB ( kidney, ureter, bladder)  showing a  left
vesico ureteric junction calculus.
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was passed into the ureter under normal saline irrigation and passed
proximally until the calculus was visualised. Patients with intra
operative findings of difficult ureteroscope entry, dense stone
impaction, edema and bleeding were excluded from the study.
Patients who underwent balloon dilatation of the ureteric orifice
were also excluded from the study. Then pneumatic lithotripsy was
done and stone fragmentation completed. Patients with residual
stone fragments in the ureter, post procedure were excluded from the
study. Patients who underwent ureteroscopy and lithotripsy for
uncomplicated ureteric calculi were stratified into two groups.
Among the total of 70 patients, 35 patients were stented with a 5 F,
one end closed, 26 cm double J stent and 35 patients were not
stented and were followed up in the post operative period and
observed for pain, urinary frequency, hematuria and fever . All
patients were discharged on the second post operative day. All
patients were again reviewed two weeks later. Those patients who
were stented were advised  an X-ray KUB( kidney, ureter, bladder),
their stent position was confirmed and stent removal was done after
two week scystoscopically as an outpatient procedure.. This study
comprised of 27 vesico ureteric junction and 38 lower ureteric
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calculi. It comprises of only 5 mid ureteric calculi patients as most of
the patients who underwent ureteroscopy could not be included in
the study owing to the presence of associated edema and stone
impaction. Patients with residual stone fragments that were detected
on post operative plain X-ray KUB( kidney, ureter, bladder) were
excluded from the study.
RESULTS AND
DISCUSSION
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RESULTS
The average age of the patients in stented and non stented
groups were 36.1 and 38.5 years respectively with the age range
varying from 13 to 63 years comprising of both groups. The size of
the calculus varied from 6 to 14 mm comprising of both groups with
a average size of 8.9 mm in the stented group and 8.5 mm in the non
stented group of patients.
TABLE NO 1 -  AGE AND SIZE
STENTED
GROUP
NONSTENTED
GROUP
AVERAGESIZEOF
CALCULUS
8.9mm 8.5mm
STONE SIZE RANGE 6-14 mm 6-12 mm
AVERAGE AGE 36.1 yrs 38.5 yrs
AGE RANGE 13-56 yrs 13-63 yrs
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The composition of each group- stented and non stented
according  to  sex  was  as  follows.  Of  the  70  patients  enrolled  in  the
study, in the stented group, there were 22 males  and 13 females. In
the non stented group there were 18 male and 17 females.
TABLE NO 2 – SEX DISTRIBUTION
STENTED GROUP
NONSTENTED
GROUP
MALES 22 (62.8%) 18 (51.4%)
FEMALES 13 (37.1%) 17 (48.5%)
30
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CHART 1 : Chart showing the composition of patients
according to sex (male/female) in both stented
and non stented group
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When the side of the ureter dealt with by ureteroscopy was
taken into account, among 70 patients enrolled in the study ,the
stented group had 19  right sided and left sided ureteric calculi. In
the non stented group, there  were 18 patients with right sided calculi
and 17 patients with left sided calculi.
TABLE NO 3 – SIDE OF CALCULI
STENTED GROUP
NONSTENTED
GROUP
RIGHT SIDE 19 (54.2%) 18 (51.4%)
LEFT SIDE 16 (45.7%) 17 (48.5%)
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With regard to location of the calculus, most of the patients
comprised of lower ureteric (38) and vesico ureteric junction calculi
(27) and few (5) mid ureteric calculi.  The number of patients with
mid ureteric calculi was low compared to lower and  vesico ureteric
junction calculi in the study as the cases with mid ureteric calculi
were complicated in most of the instances. The composition is as
follows.
TABLE NO 4 – SITE OF CALCULI
STENTED
GROUP
NONSTENTED GROUP
LOWER URETERIC 20(57.1%) 18 (51.4%))
VESICO
URETERIC
JUNCTION
CALCULI
12(34.2%) 15 (42.8%)
MID URETERIC 3  (8.5%) 2 (5.7%)
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All the enrolled 70 patients with regard to distribution
according to age, stone size, stone location, side of the stone and sex
were stratified into non stented and stented groups. The operative
procedure and associated complications were explained to the
patient and formal informed written consent was obtained.
CHART 2 :  Chart showing the distribution of patients in
the study group (both stented and non stented)
with respect to side of calculus (right and left )
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CHART  3 :  Chart showing distribution of  patients in the
study group (stented and non stented)
according to the site of calculus (mid ureter,
lower ureter, vesico ureteric junction)
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The parameters that were studied in the patients were urinary
frequency (irritative lower urinary tract symptom), loin pain, fever
and hematuria. The patients were  evaluated for the above
parameters in the post operative period and again after two weeks ,
when they were reviewed. Ideally the incidence of stricture
formation has to be taken into account as a complication following
ureteroscopic instrumentation. But in our study the incidence of
stricture in the ureter following ureteroscopy was not taken into
account as the period of study has to be extended.
Meanwhile, the patients who were symptomatic with respect
to the above mentioned parameters who attended the out patient
clinic in the intervening two weeks period were also taken into
account. The number of patients who were symptomatic with respect
to the parameters mentioned were entered in the study in both
stented and non stented group and were compared. Their statistical
significance was calculated by the chi square test.
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The overall incidence of the symptoms mentioned (urinary
frequency, pain, hematuria and fever) among both the group of
patients who were enrolled in the study was as follows.
TABLE NO 5 – STUDY PARAMETERS
STENTED NON STENTED
FREQUENCY 18 (51.4%) 5 (14.2%)
PAIN 17 (48.5%) 6 (17.1%)
FEVER 10 (28.5%) 4 (11.4%)
HEMATURIA 7 (20%) 2 (5.7%)
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FREQUENCY:
The symptom of  urinary frequency was noted in 18 out of 35
stented patients (51.4%)and 5 out of 35 (14.2%) non stented
patients. It is generally said that presence of a stent coiled inside the
bladder causes irritative lower urinary tract symptom of urinary
frequency. This symptom is more pronounced in patients were the
intravesical portion of the stent is longer and particularly if the stent
crosses the midline of the bladder and irritates the trigone. Among
the 23 patients who had urinary frequency, 6 patients ( 5 stented and
1 non stented ) had severe symptoms and attended the out patient
clinic. They were evaluated with urine analysis, and were treated
with alpha receptor blocker Tamsulosin 0.4 mg once daily. Among
the 6 patients, 2 patients had urinary tract infection that was
documented by culture and sensitivity and treated with culture
specific oral antibiotics.
The statistical analysis of the symptom of frequency in the
study group was as follows.
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TABLE NO 6- COMPARISON OF STENTED AND NON
STENTED PATIENTS FOR URINARY FREQUENCY
p=0.001
Graphical representation of the incidence of urinary frequency in
the study group is as follows:
STENT
STATUS
FREQUENCY
ABSENT
FREQUENCY
PRESENT
TOTAL
Non
stented
30 5 35
stented 17 18 35
total 47 23 70
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CHART 4:  Chart depicting incidence of the symptom of
frequency in the study group (both stented and
non stented) . frequency was observed more in
the stented group (18) than in the non stented
group (5). statistical significance (p=0.001) was
noted.
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The statistical analysis for urinary frequency in comparing
both groups revealed statistical significance  (p<0.005), as calculated
by chi square test.
PAIN:
The symptom of pain, particularly ipsilateral loin  and
suprapubic pain was noted in 17 out of 35 (48.5%)  stented patients
and 6 out of 35 (17.1%) non stented patients. The incidence of pain
could be attributed to both procedural pain and stent related pain. .
But, it was noted that the incidence of pain in the stented group was
substantially higher (48.5%) compared to the non stented (17.1%)
group. All 23 patients ( 17 stented and 6 non stented patients) were
treated with oral dicyclomine10 mg given twice daily and oral
paracetamol 500 mg given twice daily for control of pain.  In 4
patients the pain was severe , and they were treated with oral non
steroidal anti inflammatory drugs. Statistical analysis of pain
comparing both groups showed the following results.
Plain X-ray KUB (kidney, ureter, bladder) showing a left
ureteric DJ stent, the lower end was seen protruding into
the urethra. This patient had severe urinary frequency
and urgency.
Plain  X-ray KUB ( kidney, ureter, bladder)  showing  a
left ureteric DJ stent with the intra vesical portion seen to
cross the midline. This patient had severe urinary
frequency.
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TABLE NO 7 –COMPARISON OF STENTED AND NON
STENTED PATIENTS FOR PAIN
p=0.004
The results showed that the incidence of pain was statistically
significant (p<0.005) in the stented group compared to the non
stented group. Percentage wise, incidence of pain in the stented
group was substantially higher (48.5%) compared to the non stented
(17.1%) group.
Stent status Pain absent Pain present total
Non stented 29 6 35
stented 18 17 35
total 47 23 70
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CHART 5 :  Chart showing the incidence of pain in the
study group (stented and non stented). pain
in the stented group was observed in 17
stented patients compared to 6 non stented
patients . statistical significance was noted
(p=0.004)
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FEVER:
Among the 70 patients enrolled in the study, 10 out of 35
patients in the stented group (28.5%) and 4 out of 35 (11.4%)
patients in the non stented group had fever. Fever in the study group
patients varied from a temperature range of  99 F to 100.8 F with a
mean temperature of  99.6 F. Among the 14 patients with fever, 3
patients were admitted and treated with culture sensitive parenteral
antibiotics. In all 14 patients with fever, urine culture and sensitivity
was  done  and  10  patients  were  found  to  be  culture  positive  (8
patients for Escherichia coli, 2 patients for Klebsiella species)and
treated with oral antibiotics in 7 patients and parenteral antibiotics in
3 patients.
Fever can be attributed to both the possibility of infection
related to the procedure and stent related infection. Statistical
analysis of fever in comparing both groups yielded the following
results.
Plain  X-ray KUB (kidney, ureter, bladder) showing a
right ureteric DJ stent with stone fragments in the distal
portion of the stent. This patient was excluded from the
study.
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TABLE NO 8 – COMPARISON OF STENTED AND NON
STENTED PATIENTS FOR FEVER
p=0.65
 From the study group, it was made out that the incidence of
fever was more in the stented group compared to the non stented
group (28.5% vs 11.4%) . But the outcomes were not statistically
significant (p>0.005), as calculated by the chi square test.
Stent status No fever Fever present Total
Non stented 31 4 35
stented 25 10 35
total 56 14 70
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CHART 6: Chart showing the incidence of fever in the
study group ( both stented and non stented).10
stented and 4 non stented patients had fever . it
was not statistically significant (p=0.65)
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HEMATURIA:
Evaluation with regard to the symptom of hematuria showed
that , the incidence was 7 out of 35 (20%) patients in the stented
group and 2 out of  35 (5.7%) in the non stented group. All 9
patients were enrolled positivity for hematuria only after urine
analysis showed more than 3 RBCs/high power field. In fact to be
precise, 13 patients gave history of hematuria and 4 patients were
excluded positivity after their urine analysis was negative for RBCs.
The symptom of hematuria is due to the stent causing irritative
effects on the bladder mucosa as well as procedure related. Those
patients who had obvious bleeding intra operatively during the
procedure were excluded from the study, as those patients had to be
invariably stented to prevent obstruction , as a result of possible clot
retention. All 9 patients with hematuria were treated with
reassurance, rest and advised plenty of oral fluids.
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TABLE NO 9 - COMPARISON OF STENTED AND NON
STENTED     PATIENTS FOR HEMATURIA.
p=0.67
Although the incidence of hematuria was considerably higher
in the stented than in the non stented group (20% vs 5.7%), it was
not statistically significant (p>0.005), as calculated by the chi square
test.
Stent status No hematuria Hematuriapresent Total
Non stented 33 2 35
Stented 28 7 35
Total 61 9 70
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CHART 7:   Chart depicting the incidence of hematuria in
the study group (stented and non stented).
hematuria was observed in 7 stented and 2 non
stented patients . statistical significance was not
established (p=0.67)
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DISCUSSION
Urolithiasis is one of the most common and oldest diseases of
urinary tract(29).  Now days, ureteroscopy is one of the common
procedures among variety of endourological surgeries and is being
done for number of indications including ureteroscopic stone
fragmentation and its removal. Stenting after ureteroscopy has been
recommended to prevent the development of ureteral stricture, it also
facilitates passage of stone fragments and promotes ureteral healing
after ureteroscopy. In 1999, Hosking et al have concluded that
routine placement of ureteral stent following uncomplicated
ureteroscopic removal of distal ureteral stones was not necessary(30)
and  same  observation  was  seen  in  our  study.  A  few  prospective
randomized trials have recently been reported in the literature, and
all showed no difference in stone free status between stented and
nonstented groups(31,32,33). In our study, irritative voiding symptom of
urinary frequency in the stented group was observed in 51.4% of
patients, as compared to  14.2% of patients in the non-stented group.
These results were comparable with all above mentioned studies
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where they claim that post operative pain and irritative voiding
symptoms were reduced with omission of ureteric stents.
Routine placement of ureteral stent after ureteroscopy
increases the overall cost of the procedure(34).  In our study ,non
stented group was cost effective as compared to stented group and
same  was  reported  by  Netto  et  al (35).  They  assessed  that  cost
effectiveness of ureteroscopy in non stented group was cheaper by
30%. Furthermore, removal of the stent using local anesthesia is
more traumatic than the initial ureteroscopy procedure using
regional (spinal) anesthesia. The patient has to be subjected to yet
another invasive procedure, with its attendant  complications of
urinary tract infection, fever and stricture formation in the long term.
The incidence of hematuria and fever are higher in the stented than
in the non stented group, as witnessed in our study, even though
there is not enough statistical significance.
Postoperative pain in our study was less in non stented group
(17.1%) as compared to stented group(48.5%). The increased
intrapelvicrenal pressure, especially while voiding, explains this
increased incidence of pain. Ramsay et al demonstrated in porcine
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model that ureteral intubation caused an increase in intrapelvic renal
pressure which was the reason for more pain in the patients with
stent(36).
The development of ureteral stricture is a well-established
longterm complication following ureteroscopy. However, the
incidence of ureteral stricture is dramatically decreased in recent
years due to the advancements made in endourological technology.
In this study no stricture formation was found as compared to the
other studies. However, the period of follow up has to be extended
for assessing stricture of the ureter. Hence, stricture was not included
as a variable in our study.
CONCLUSION
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CONCLUSION
? Stenting of the ureter has its own side effects of irritative
voiding symptoms, pain, hematuria, urinary tract infection,
fever.
? Stenting of the ureter following ureteroscopy has to be done
taking factors like stone site, size, degree of impaction ,
bleeding, associated edema, difficulty encountered in
negotiating the ureteric orifice into consideration .
? The side effects and complications associated with stenting of
the ureter should be weighed against the advantages offered by
stenting, depending on the intra operative ureteroscopy
findings.
? Routine placement of ureteral stent is not necessary in
uncomplicated cases of ureteric calculi following
ureteroscopy, the decision being made on the basis of intra
operative findings, where the risks clearly outweigh the
benefits offered by stenting.
? The option of not stenting the patient following ureteroscopy
should be considered for lower and distal ureteric calculi than
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proximal ureteric calculi, clearly the decision being based on
intra operative findings.
? Stented patients need yet another invasive procedure for stent
removal, which increases patient morbidity as well as the
overall cost of the procedure.
APPENDIX
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PROFORMA
1) Name:
2) Age :
3) OP/ IP No:
4) Address and Phone No:
5) History:
- H/O loin pain
- H/O dysuria / hematuria / calculuria
- H/O Diabetes / Hypertension
6) General Physical Examination :
- Pallor / icterus / cyanosis / Pulse / B.P.
7) Systemic Examination :
- CVS :
- RS:
- CNS:
- P/A :
Examination of Ext. Genitalia and Testes:
-  Digital Rectal Examination :
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8)    Investigations :
- CBC
- RBS RFT
- Plain X-ray KUB
Stone side
Site
Size
- Ultrasound KUB
Stone side
Site
Size
hydroureteronephrosis-grade
- Intra Venous Urogram
Stone side
Site
Size
60
hydroureteronephrosis-grade
excretion status of both kidneys
-     INTRAOPERATIVE FINDINGS
Stone side
Site
Size
Stent status (stented / non stented)
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MASTER CHART
MASTER CHART FOR
STENTED GROUP OF
PATIENTS
Serial No Name Age/Sex IP No Diagnosis Size of
calculus
pain frequency hematuria fever
1 subramani 38/m 30778 right lower ureteric calculus 6 mm yes no no no
2 shanmugam 30/m 33283 left midureteric caculus 8 mm yes yes no no
3 sakthivel 36/m 35057 left midureteric calculus 8 mm no no no no
4 thirunavukarasu 25/m 37145 right vesicoureteric Junction calculus 7 mm yes yes no no
5 saroja 53/f 36865 left vesicoureteric Junction calculus 6 mm no no no no
6 pavithra 20/f 38274 left lower ureteric calculus 9 mm yes yes no yes
7 william john 47/m 39381 left lower ureretic calculus 6 mm yes no no yes
8 venkatesan 35/m 38769 right lower ureteric calculus 6 mm no no no no
9 thanikachalam 47/m 40470 left lower ureretic calculus 7 mm yes yes yes yes
10 parthasarathy 56/m 41543 right vesicoureteric Junction calculus 8 mm yes no yes yes
11 shakthi 41/m 41302 right vesicoureteric Junction calculus 9 mm yes yes yes no
12 solai 43/m 42737 left vesicoureteric Junction calculus 8 mm no yes no no
13 bhakthavakchalam 28/m 44507 right vesicoureteric Junction calculus 9 mm yes no yes no
14 chitra 24/f 3972 right vesicoureteric Junction calculus 9 mm yes yes no yes
15 kannan 23/m 3070 right vesicoureteric Junction calculus 7 mm yes yes no no
16 devi 50/f 4806 right vesicoureteric Junction calculus 10 mm yes yes no yes
17 kamali 13/f 4841 right vesicoureteric Junction calculus 7 mm no no no no
18 vijaya 35/f 5684 right vesicoureteric Junction calculus 10 mm yes yes no no
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19 rafeeq ahmed 43/m 5352 right lower ureteric calculus 9 mm no no no no
20 venkatesan 40/m 6003 left lower ureretic calculus 8 mm no no yes yes
21 kamala 50/f 6116 right lower ureteric calculus 14 mm no yes no no
22 prem kumar 23/m 6505 left vesicoureteric Junction calculus 8 mm no no yes no
23 selvi 21/f 7125 right lower ureteric calculus 7 mm no no no no
24 sethulakshmi 29/f 6658 right lower ureteric calculus 10 mm no yes yes no
25 sujatha 41/f 9142 left lower ureteric calculus 12 mm yes yes no no
26 gowthami 24/f 9089 right lower ureteric calculus 9 mm no no no no
27 venkatesan 48/m 10075 left lower ureteric calculus 9 mm no no no yes
28 ravi kumar 52/m 9112 left lower ureteric calculus 14 mm yes yes no no
29 elumalai 35/m 11293 right lower ureteric calculus 9 mm no no no yes
30 allabasha 38/m 11548 left lower ureteric calculus 10 mm yes yes no no
31 murugammal 52/f 11522 left lower ureteric calculus 9 mm no yes no no
32 yuvaraj 25/m 16741 left midureteric calculus 6 mm no no no no
33 vijaya 31/f 17754 left lower ureteric calculus 9 mm no yes no no
34 arun 18/m 17645 right lower ureteric calculus 11 mm yes yes no yes
35 iyappan 14/m 17626 left lower ureteric calculus 11 mm no no no no
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MASTER CHART FOR
NON STENTED GROUP
OF PATIENTS
Serial no Name Age/Sex IP no Diagnosis size of
calculus
pain frequency hematuria fever
1 shanthi 30/F 28335 right lower ureteric calculus 8 mm no no no no
2 baskar 33/M 29168 right vesicoureteric junction calculus 8 mm no no no no
3 sundari 45/M 36784 left lower ureteric calculus 8 mm yes no no no
4 jeyalakshmi 15/F 2978 right vesicoureteric junction calculus 7 mm no no no no
5 kumar 21/M 5865 right lower ureteric calculus 12 mm no yes yes no
6 ajay 13/M 6062 left vesicoureteric junction calculus 9 mm yes no no no
7 surya 27/M 8589 left vesicoureteric junction calculus 10 mm no yes no yes
8 muniyammal 47/F 9115 left lower ureteric calculus 10 mm yes no no no
9 chitra 2/F 16090 left lower ureteric calculus 9 mm no yes yes no
10 arumugam 30/M 15894 right vesicoureteric junction calculus 7 mm yes no no no
11 hussaun 28/M 17149 left lower ureteric calculus 6 mm no no no no
12 mathias 50/M 17618 left lower ureteric calculus 7 mm no no no no
13 sethulakshmi 27/F 17630 right lower ureteric calculus 8 mm no yes no no
14 ramesh 29/M 19167 left lower ureteric calculus 9 mm no yes no yes
15 arulmozhi 49/F 18660 left lower ureteric calculus 9 mm no no no no
16 narayanan 24/M 19170 left vesicoureteric junction calculus 8 mm no no no no
17 amala 25/F 20458 right mid ureteric calculus 7 mm no no no no
18 kamala 35/F 20809 right mid ureteric calculus 6 mm no no no no
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19 maheshwari 45/F 21331 right lower ureteric calculus 11 mm yes no no yes
20 gnanaprakasam 55/M 22083 right vesicoureteric junction calculus 8 mm no no no no
21 peter 63/M 24182 right lower ureteric calculus 9 mm yes no no no
22 kaveri 42/F 24228 left vesicoureteric junction calculus 8 mm no no no no
23 neela 46/F 28476 left vesicoureteric junction calculus 9 mm no no no yes
24 kamalakannan 34/M 33610 left lower ureteric calculus 6 mm no no no no
25 devi 53/F 30754 left vesicoureteric junction calculus 7 mm no no no no
26 raja 27/M 40076 right lower ureteric calculus 6 mm no no no no
27 radha 18/F 39882 right lower ureteric calculus 6 mm no no no no
28 vairamuthu 23/M 41695 right vesicoureteric junction calculus 6 mm no no no no
29 lingam 49/M 41479 left lower ureteric calculus 6 mm no no no no
30 prabhu 22/M 42580 left vesicoureteric junction calculus 6 mm no no no no
31 vijayalakshmi 43/F 1419 right lower ureteric calculus 7 mm no no no no
32 siluvai antony 51/M 51439 left lower ureteric calculus 7 mm no no no no
33 sandhya 23/F 51438 right vesicoureteric junction calculus 8 mm no no no no
34 jackson paul 25/M 5295 right vesicoureteric junction calculus 8 mm no no no no
35 sekar 43/M 57045 right vesicoureteric junction calculus 7 mm no no no no
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